Literature DB >> 9403199

Cerebral cavernous hemangiomas in childhood. Clinical presentation and therapeutic considerations.

L M Smit1, F J Halbertsma.   

Abstract

Cerebral cavernous hemangiomas (CCH) are relatively rare vascular hamartomas. Since the introduction of MRI there has been an increase in the number of case reports of CCH in the medical literature. CCH are often asymptomatic; they may, however, cause epilepsy or neurological deficits due to their space-occupying effects or hemorrhagic sequelae. The tendency of CCH to bleed has been well recognized, though gross hemorrhage is infrequent owing to the relatively low blood pressure and small blood flow in CCH. MRI findings of a CCH are characteristic and can differentiate the lesions from other vascular abnormalities. To date, there has been no consensus on indications for surgical intervention. Three cases are presented, which together demonstrate by their different presentation, clinical course and MRI findings that each patient with a CCH requires an individually tailored management. Presentation, clinical course and accessibility for operation are the factors that determine whether a surgical or a conservative approach should be adopted.

Entities:  

Mesh:

Year:  1997        PMID: 9403199     DOI: 10.1007/s003810050130

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  2 in total

1.  Management of intracranial cavernous malformation in pediatric patients.

Authors:  Jae-Whan Lee; Dong-Seok Kim; Kyu-Won Shim; Jong-Hee Chang; Seung-Kon Huh; Yong-Gou Park; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2007-09-18       Impact factor: 1.475

2.  Treatment and outcome of children with cerebral cavernomas: a survey on 32 patients.

Authors:  Alessandro Consales; Gianluca Piatelli; Marcello Ravegnani; Marco Pavanello; Pasquale Striano; Maria Luisa Zoli; Valeria Capra; Andrea Rossi; Maria Luisa Garrè; Maria Grazia Calevo; Armando Cama
Journal:  Neurol Sci       Date:  2009-10-16       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.